Celcuity Inc. (CELC): R&D Expense
$145.00M
Year ended 2025-12-31
+60.2%
3-year compound annual growth
+80.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $145.00M | +39.1% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $104.20M | +72.0% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $60.59M | +71.7% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $35.29M | +37.0% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $25.76M | +235.2% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $7.68M | +22.6% | 2022-03-23, From 2020-01-01 |
| 2019-12-31 | $6.27M | -0.9% | 2021-02-16, From 2019-01-01 |
| 2018-12-31 | $6.33M | +27.0% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $4.98M | +62.5% | 2019-03-01, From 2017-01-01 |
| 2016-12-31 | $3.06M | n/a | 2018-03-15, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Celcuity Inc. (CELC) | 2025-12-31 | $145.00M | +39.1% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $71.43M | -1.5% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $51.85M | -0.4% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $49.38M | +34.9% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $50.26M | +2.8% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $101.58M | -10.8% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $53.91M | +10.4% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $70.81M | +2.2% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $364.19M | +4.7% |
Compare CELC, CDNA, CSTL, BLLN side by side · Screen every company in Services-Medical Laboratories ↗